ConductScience.org, home

Paper40964483

State of the art in treatment of small cell lung cancer.

Behrouzi R and 1 other. Ther Adv Med Oncol, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. State of the art in treatment of small cell lung cancer. Papers, record 40964483. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40964483

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
State of the art in treatment of small cell lung cancer.
PubMed
Journal
Ther Adv Med Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.15, provisional
iCite
Revised in PubMed
2025-09-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Behrouzi RRoyahttps://orcid.org/0000-0002-1978-6539
2Blackhall FFiona

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References159

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118786981Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.Thorax2009https://conductscience.org/library/papers/18786981PubMed
234335926Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations.J Cancer2021https://conductscience.org/library/papers/34335926PubMed
324882383Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.Lung Cancer2014https://conductscience.org/library/papers/24882383PubMed
433439693Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).J Clin Oncol2021https://conductscience.org/library/papers/33439693PubMed
533864941Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.Ann Oncol2021https://conductscience.org/library/papers/33864941PubMed
637146473Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.Lung Cancer2023https://conductscience.org/library/papers/37146473PubMed
739268857Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.N Engl J Med2024https://conductscience.org/library/papers/39268857PubMed
810441603Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.N Engl J Med1999https://conductscience.org/library/papers/10441603PubMed
935279527Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.ESMO Open2022https://conductscience.org/library/papers/35279527PubMed
1037037178Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.Lung Cancer2023https://conductscience.org/library/papers/37037178PubMed
1139541202Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.JAMA Oncol2025https://conductscience.org/library/papers/39541202PubMed
1228642008Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.Lancet Oncol2017https://conductscience.org/library/papers/28642008PubMed
1330523756Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.J Clin Oncol2019https://conductscience.org/library/papers/30523756PubMed
1430217489A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.J Thorac Oncol2019https://conductscience.org/library/papers/30217489PubMed
1538366589Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.Cancer Cell2024https://conductscience.org/library/papers/38366589PubMed
1637027065A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients.Clin Exp Med2023https://conductscience.org/library/papers/37027065PubMed
1735576956
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol2022https://conductscience.org/library/papers/35576956PubMed
1822473169Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.J Clin Oncol2012https://conductscience.org/library/papers/22473169PubMed
1911008007A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.Lung Cancer2000https://conductscience.org/library/papers/11008007PubMed
2037981084Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis.Radiother Oncol2024https://conductscience.org/library/papers/37981084PubMed

See all 159 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42882853AI-Driven Multi-Omics Approaches for Deciphering Small-Cell Lung Cancer Heterogeneity Using Nucleic-Acid-Based Features.Cancers (Basel)2026https://conductscience.org/library/papers/42882853PubMed
42813501From Real World Data to Real Impact: A Co-Medication Framework for Lung Cancer to Advance DDI Assessment and Patient-Centric Drug Development.Clin Transl Sci2026https://conductscience.org/library/papers/42813501PubMed
42649862Small Cell Lung Cancer in Transition: Recent Advances in Biology, Treatment, and Precision Medicine.Cancers (Basel)2026https://conductscience.org/library/papers/42649862PubMed
42582332DLL3-directed immune redirection in small-cell lung cancer: a lineage-defined vulnerability that doubles as an escape route.Front Immunol2026https://conductscience.org/library/papers/42582332PubMed
42558713Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials.Front Immunol2026https://conductscience.org/library/papers/42558713PubMed
42088497The application and challenges of immune checkpoint inhibitors in lung cancer therapy.Front Immunol2026https://conductscience.org/library/papers/42088497PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40964483

GET https://conductscience.org/api/papers/v1/40964483/references?page=2